# US 2011/0257372 A1 · Immunoglobulins devoid of light chains

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2011/0257372 A1
- Document ID: US20110257372A1
- Status: Published application
- Kind: A1
- Application number: 13/078,665
- Filed: 2011-04-01
- Published: 2011-10-20
- Earliest claimed: 1992-08-21
- Assignees: Vrije Universiteit Brussel
- Inventors: Cecile Casterman; Raymond Hamers
- Web page: https://patentgrep.com/patent/US20110257372A1

## CPC

- C07K 16/20: from protozoa
- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- A61K 2039/505: {comprising antibodies}
- C07K 2317/22: from camelids, e.g. camel, llama or dromedary
- C07K 2317/50: characterized by immunoglobulin fragments
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/567: Framework region [FR]
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

There is provided an isolated immunoglobulin comprising two heavy polypeptide chains sufficient for the formation of a complete antigen binding site or several antigen binding sites, wherein the immunoglobulin is further devoid of light polypeptide chains.

## Claims

### Claim 1

A ligand comprising a single variable domain, wherein the single variable domain specifically binds to an antigen, and the variable domain comprises an affinity of an immunoglobulin that has undergone affinity maturation in vivo.

### Claim 2 (depends on 1)

The ligand of claim 1, wherein the antigen is selected from the group consisting of human protein, animal protein, determined antigens, antigens of pathological agents, bacteria, viruses, parasites, envelope glycoproteins of viruses, protein, hapten, carbohydrate, nucleic acid, galactosyl β-1-3-galactose epitope, myeloma immunoglobulin epitope, insect gut antigen, CD4 cells.

### Claim 3

A dual specific ligand comprising a first single variable domain and a second a single variable domain where at least one of the first single variable domain and the second single variable domain comprises an affinity of an immunoglobulin that has undergone affinity maturation in vivo.

### Claim 4 (depends on 3)

The dual specific ligand of claim 3, wherein said first single variable domain specifically binds to an antigen selected from the group consisting of, human, protein, animal protein, determined antigens, antigens of pathological agents, bacteria, viruses, parasites, envelope glycoproteins of viruses, protein, hapten, carbohydrate, nucleic acid, galactosyl α-1-3-galactose epitope, myeloma immunoglobulin epitope, insect gut antigen, CD4 cells; and wherein said second single variable domain specifically binds to an antigen selected from the group consisting of, human, protein, animal protein, determined antigens, antigens of pathological agents, bacteria, viruses, parasites, envelope glycoproteins of viruses, protein, hapten, carbohydrate, nucleic acid, galactosyl α-1-3-galactose epitope, myeloma immunoglobulin epitope, insect gut antigen, CD4 cells.

### Claim 5

A dual specific ligand comprising a first single variable domain and a second single variable domain, wherein the first single variable domain specifically binds to an antigen and the second single variable domain specifically binds to an antigen, wherein at least one of the first single variable domain and the second single variable domain comprises an affinity of an immunoglobulin that has undergone affinity maturation in vivo.

### Claim 6 (depends on 5)

The dual specific ligand of claim 5, wherein said first single variable domain specifically binds to an antigen selected from the group consisting of human protein, animal protein, determined antigens, antigens of pathological agents, bacteria, viruses, parasites, envelope glycoproteins of viruses, protein, hapten, carbohydrate, nucleic acid, galactosyl α-1-3-galactose epitope, myeloma immunoglobulin epitope, insect gut antigen, CD4 cells; and wherein said second single variable domain specifically binds to an antigen selected from the group consisting of human protein, animal protein, determined antigens, antigens of pathological agents, bacteria, viruses, parasites, envelope glycoproteins of viruses, protein, hapten, carbohydrate, nucleic acid, galactosyl α-1-3-galactose epitope, myeloma immunoglobulin epitope, insect gut antigen, CD4 cells.
